The BinaxNow antigen test is fast and acceptably accurate – but above all, cheap.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.
Cellex wins the race to get the FDA’s buy-in for a blood test to pinpoint immunity.
The FDA is loosening its rules on the authorisation of diagnostic tests for the new coronavirus, but it is still some way behind Europe.
There is a ready market for blood tests that do not involve putting a needle to a vein. Can a new partnership meet the demand?